GoAI
Get started
Cosmos Health Inc. logo

Cosmos Health Inc.

COSM

NASDAQHealthcareMedical - Pharmaceuticals

Open in GoAI

Regular session

$0.2139

−$0.0076 · -3.43%

Aug 24, 3:57 PM ET

COSM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

58

Fair Value

Momentum

45

Neutral

Sentiment

57

Mixed

Risk resilience

7

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
GR
CEO
Grigorios Siokas
Listed since
Jul 23, 2010
Employees
163

Market position

Day range

Current $0.2139

52-week range

Current $0.2139

Open
$0.227
Previous close
$0.2215
Volume
2.33M
0.26× average
Average volume
8.83M
Average daily volume
Market cap
11.64M USD
Beta
4.17
Market reference 1
50-day average
$0.2239
-4.47% below average
200-day average
$0.3762
-43.14% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
34.34M USD
EV / EBITDA
-2.27×
Earnings yield
-126.92%
Free cash flow yield
-56.37%

Profitability & efficiency

Return on equity
-103.91%
Return on assets
-29.24%
Return on invested capital
-40.39%

Financial health

Current ratio
1×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends20%-2%-24%-46%Gross margin, FY2021: 14.81%Gross margin, FY2022: 11.83%Gross margin, FY2023: 8.15%Gross margin, FY2024: 7.92%Gross margin, FY2025: 12.10%Operating margin, FY2021: -8.06%Operating margin, FY2022: -14.84%Operating margin, FY2023: -40.90%Operating margin, FY2024: -28.56%Operating margin, FY2025: -25.34%Net margin, FY2021: -14.16%Net margin, FY2022: -27.47%Net margin, FY2023: -34.74%Net margin, FY2024: -29.73%Net margin, FY2025: -29.33%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 14.81%. Gross margin FY2022 11.83%. Gross margin FY2023 8.15%. Gross margin FY2024 7.92%. Gross margin FY2025 12.10%. Operating margin FY2021 -8.06%. Operating margin FY2022 -14.84%. Operating margin FY2023 -40.90%. Operating margin FY2024 -28.56%. Operating margin FY2025 -25.34%. Net margin FY2021 -14.16%. Net margin FY2022 -27.47%. Net margin FY2023 -34.74%. Net margin FY2024 -29.73%. Net margin FY2025 -29.33%.

Income trends

Revenue

65.27M USD+19.93%

Operating income

−16.54M USD-6.41%

Net income

−19.14M USD-18.30%
Income trends across reported periods73.98M USD39.14M USD4.3M USD−30.54M USDRevenue, FY2021: 56.24M USDRevenue, FY2022: 50.35M USDRevenue, FY2023: 53.38M USDRevenue, FY2024: 54.43M USDRevenue, FY2025: 65.27M USDOperating income, FY2021: −4.53M USDOperating income, FY2022: −7.47M USDOperating income, FY2023: −21.83M USDOperating income, FY2024: −15.54M USDOperating income, FY2025: −16.54M USDNet income, FY2021: −7.96M USDNet income, FY2022: −13.83M USDNet income, FY2023: −18.54M USDNet income, FY2024: −16.18M USDNet income, FY2025: −19.14M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 56.24M USD. Revenue FY2022 50.35M USD. Revenue FY2023 53.38M USD. Revenue FY2024 54.43M USD. Revenue FY2025 65.27M USD. Operating income FY2021 −4.53M USD. Operating income FY2022 −7.47M USD. Operating income FY2023 −21.83M USD. Operating income FY2024 −15.54M USD. Operating income FY2025 −16.54M USD. Net income FY2021 −7.96M USD. Net income FY2022 −13.83M USD. Net income FY2023 −18.54M USD. Net income FY2024 −16.18M USD. Net income FY2025 −19.14M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue65.27M USD54.43M USD53.38M USD50.35M USD56.24M USD
Cost of goods sold57.38M USD50.12M USD49.03M USD44.39M USD47.91M USD
Gross profit7.9M USD4.31M USD4.35M USD5.96M USD8.33M USD
Research and development519.36K USD533.29K USD———
Selling, general, and administrative22.55M USD12.09M USD25.57M USD13.24M USD12.41M USD
Operating expenses24.44M USD19.86M USD26.18M USD13.43M USD12.86M USD
Interest income396.41K USD406.45K USD662.86K USD236.35K USD46.32K USD
Interest expense2.62M USD1.01M USD866.48K USD3.97M USD3.58M USD
Depreciation and amortization1.37M USD1.25M USD614.38K USD188.89K USD449.69K USD
Operating income−16.54M USD−15.54M USD−21.83M USD−7.47M USD−4.53M USD
Net income−19.14M USD−16.18M USD−18.54M USD−13.83M USD−7.96M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 8 misses, 2 met estimates
Average EPS surprise
-381.05%
10 comparable reports
Latest EPS result
-0.1
Estimate -0.1 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.05-0.15-0.34-0.54Q2 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ2 '26MissQ2 '26MissQ3 '26MetQ4 '26Estimate
Q2 2025, reported Apr 15, 2025: actual -0.5, estimate -0.09, surprise -455.56%, Miss. Q2 2025, reported May 15, 2025: actual -0.031, estimate -0.03, surprise -4.67%, Miss. Q3 2025, reported Aug 15, 2025: actual -0.098, estimate 0.01, surprise -1084.00%, Miss. Q4 2025, reported Nov 14, 2025: actual -0.17, estimate -0.01, surprise -1600.00%, Miss. Q2 2026, reported Apr 15, 2026: actual -0.14, estimate -0.04, surprise -250.00%, Miss. Q2 2026, reported May 20, 2026: actual -0.02, estimate -0.01, surprise -100.00%, Miss. Q3 2026, reported Aug 19, 2026: actual -0.1, estimate -0.1, surprise 0.00%, Met estimate. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.05, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates21.72M18.77M15.82M12.88MQ2 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ2 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q2 2025, reported Apr 15, 2025: actual 14.22M USD, estimate 14.5M USD, surprise -1.90%, Miss. Q2 2025, reported May 15, 2025: actual 13.71M USD, estimate 15.5M USD, surprise -11.53%, Miss. Q3 2025, reported Aug 15, 2025: actual 14.75M USD, estimate 17.48M USD, surprise -15.62%, Miss. Q4 2025, reported Nov 14, 2025: actual 17.11M USD, estimate 16.4M USD, surprise +4.33%, Beat. Q2 2026, reported Apr 15, 2026: actual 19.7M USD, estimate 18.82M USD, surprise +4.68%, Beat. Q2 2026, reported May 20, 2026: actual 17.9M USD, estimate 17.93M USD, surprise -0.16%, Miss. Q3 2026, reported Aug 19, 2026: actual 19.32M USD, estimate 18.99M USD, surprise +1.75%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate 20.89M USD, surprise —, Comparison unavailable.

COSM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$444.52

+1.18%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.35

+0.16%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.11

+0.01%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$374.73

-1.08%

Sanofi logo

SNY

Sanofi

$45.6748

-0.38%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$829.66

-0.53%

ETFs holding COSM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
65.57K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.72-0.74%

Continue in GoAI

Research COSM

research.disclaimer